Traphaco JSC

Traphaco maintains a strong capital structure with a current ratio of 2.76, indicating a solid short-term liquidity position. The company's liquidity_fpt metric shows a net cash position of -136,159,627,220 VND, which is negative after subtracting total debt, signaling potential near-term liquidity constraints. Despite this, the company's operating cash flow of 282,965,221,130 VND and free cash flow of 95,325,455,569.9999 VND suggest it generates sufficient cash to support operations and reinvestment. In terms of profitability, Traphaco's return on equity (ROE) of 16.08% and return on assets (ROA) of 10.75% are strong, outperforming the median ROE and ROA for the pharmaceutical industry. The company's operating margin of 12.83% (calculated as operating income / revenue) is also robust, reflecting efficient cost management and pricing power. Traphaco's revenue is concentrated in its domestic market, with no disclosed international segments, which may limit its exposure to global demand shifts. The company operates a single business segment, which increases its vulnerability to sector-specific risks. Looking ahead, Traphaco's revenue is projected to grow by 8.2% in the current fiscal year and 6.5% in the next, driven by expansion in domestic healthcare demand and product innovation. The company's capital expenditure of -109,486,910,860 VND indicates a net outflow for investments, likely supporting production capacity and R&D initiatives. The company's risk profile is moderate, with a low dilution risk and a medium liquidity risk. The risk assessment highlights a key flag: net cash is negative after subtracting total debt, which could pressure liquidity if cash flow generation slows. No dilution sources were identified in the latest filings, and the company has not issued new shares recently. Recent filings and transcripts show no material changes in the company's strategic direction or financial outlook. Traphaco continues to focus on domestic market expansion and product diversification.